Show simple item record

dc.contributor.authorGutiérrez, HC
dc.contributor.authorVacca, I
dc.contributor.authorSchoenmacker, G
dc.contributor.authorCleal, M
dc.contributor.authorTochwin, A
dc.contributor.authorO'Connor, B
dc.contributor.authorYoung, AMJ
dc.contributor.authorVasquez, AA
dc.contributor.authorWinter, MJ
dc.contributor.authorParker, MO
dc.contributor.authorNorton, WHJ
dc.date.accessioned2019-11-26T14:05:53Z
dc.date.issued2019-11-01
dc.description.abstractAlthough aggression is a common symptom of psychiatric disorders the drugs available to treat it are non-specific and can have unwanted side effects. In this study we have used a behavioural platform in a phenotypic screen to identify drugs that can reduce zebrafish aggression without affecting locomotion. In a three tier screen of ninety-four drugs we discovered that caffeine and sildenafil can selectively reduce aggression. Caffeine also decreased attention and increased impulsivity in the 5-choice serial reaction time task whereas sildenafil showed the opposite effect. Imaging studies revealed that both caffeine and sildenafil are active in the zebrafish brain, with prominent activation of the thalamus and cerebellum evident. They also interact with 5-HT neurotransmitter signalling. In summary, we have demonstrated that juvenile zebrafish are a suitable model to screen for novel drugs to reduce aggression, with the potential to uncover the neural circuits and signalling pathways that mediate such behavioural effects.en_GB
dc.description.sponsorshipEuropean Union FP7en_GB
dc.description.sponsorshipNC3Rsen_GB
dc.identifier.citationPublished online 1 November 2019en_GB
dc.identifier.doi10.1016/j.euroneuro.2019.10.005
dc.identifier.grantnumber602805en_GB
dc.identifier.grantnumberNC/R001049/1en_GB
dc.identifier.urihttp://hdl.handle.net/10871/39811
dc.language.isoenen_GB
dc.publisherElsevier for European College of Neuropsychopharmacologyen_GB
dc.rights© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (https://creativecommons.org/licenses/by-nc-nd/4.0)en_GB
dc.subjectZebrafishen_GB
dc.subjectAggressionen_GB
dc.subjectDrug screenen_GB
dc.subjectBehaviouren_GB
dc.subjectCaffeineen_GB
dc.subjectSildenafilen_GB
dc.titleScreening for drugs to reduce zebrafish aggression identifies caffeine and sildenafilen_GB
dc.typeArticleen_GB
dc.date.available2019-11-26T14:05:53Z
dc.identifier.issn0924-977X
dc.descriptionThis is the final version. Available on open access from Elsevier via the DOI in this recorden_GB
dc.identifier.journalEuropean Neuropsychopharmacologyen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/  en_GB
dcterms.dateAccepted2019-10-10
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2019-11-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-11-26T14:02:49Z
refterms.versionFCDVoR
refterms.dateFOA2019-11-26T14:05:56Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(https://creativecommons.org/licenses/by-nc-nd/4.0)
Except where otherwise noted, this item's licence is described as © 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (https://creativecommons.org/licenses/by-nc-nd/4.0)